title: Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.
abstract: Diffuse gliomas consist of both low- and high-grade varieties, each with distinct morphological and biological features. The often extended periods of relative indolence exhibited by low-grade gliomas (LGG; WHO grade II) differ sharply from the aggressive, rapidly fatal clinical course of primary glioblastoma (GBM; WHO grade IV). Nevertheless, until recently, the molecular foundations underlying this stark biological contrast between glioma variants remained largely unknown. The discoveries of distinctive and highly recurrent genomic and epigenomic abnormalities in LGG have both informed a more accurate classification scheme and pointed to viable avenues for therapeutic development. As such, the field of neuro-oncology now seems poised to capitalize on these gains to achieve significant benefit for LGG patients. This report will briefly recount the proceedings of a workshop held in January 2013 and hosted by Accelerate Brain Cancer Cure (ABC(2)) on the subject of LGG. While much of the meeting covered recent insights into LGG biology, its focus remained on how best to advance the clinical management, whether by improved preclinical modeling, more effective targeted therapeutics and clinical trial design, or innovative imaging technology.
authors.affiliation: Corresponding author: Susan Chang, MD, Department of Neurological Surgery, UCSF Helen Diller Family Comprehensive Cancer Center, 400 Parnassus Ave., A808, San Francisco, CA 94143-0372. changs@neurosurg.ucsf.edu.
authors.forename: Jason T
authors.initials: JT
authors.lastname: Huse
authors.forename: Max
authors.initials: M
authors.lastname: Wallace
authors.forename: Kenneth D
authors.initials: KD
authors.lastname: Aldape
authors.forename: Mitchel S
authors.initials: MS
authors.lastname: Berger
authors.forename: Chetan
authors.initials: C
authors.lastname: Bettegowda
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Brat
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Cahill
authors.forename: Timothy
authors.initials: T
authors.lastname: Cloughesy
authors.forename: Daphne A
authors.initials: DA
authors.lastname: Haas-Kogan
authors.forename: Marco
authors.initials: M
authors.lastname: Marra
authors.forename: C Ryan
authors.initials: CR
authors.lastname: Miller
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Nelson
authors.forename: Sofie R
authors.initials: SR
authors.lastname: Salama
authors.forename: Riccardo
authors.initials: R
authors.lastname: Soffietti
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
authors.forename: Stephen
authors.initials: S
authors.lastname: Yip
authors.forename: Katharine
authors.initials: K
authors.lastname: Yen
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Costello
authors.forename: Susan
authors.initials: S
authors.lastname: Chang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005910:Glioma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy; D060787:Neoplasm Grading
chemical_list: D000970:Antineoplastic Agents
keywords: clinical trials; genomics; low-grade glioma; personalized medicine